New therapy for visceral leishmaniasis.
D000284:Administration, Oral; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D006801:Humans; D007194:India / Q000453:epidemiology; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000453:epidemiology; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine